BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 15834463)

  • 1. An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity.
    Gupta R; Kumar G; Kumar RS
    Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):101-18. PubMed ID: 15834463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting cancer with phosphodiesterase inhibitors.
    Savai R; Pullamsetti SS; Banat GA; Weissmann N; Ghofrani HA; Grimminger F; Schermuly RT
    Expert Opin Investig Drugs; 2010 Jan; 19(1):117-31. PubMed ID: 20001559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.
    Lugnier C
    Pharmacol Ther; 2006 Mar; 109(3):366-98. PubMed ID: 16102838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family.
    Gibson LC; Hastings SF; McPhee I; Clayton RA; Darroch CE; Mackenzie A; Mackenzie FL; Nagasawa M; Stevens PA; Mackenzie SJ
    Eur J Pharmacol; 2006 May; 538(1-3):39-42. PubMed ID: 16674936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
    de Vente J; Markerink-van Ittersum M; Vles JS
    J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterases in the central nervous system.
    Kleppisch T
    Handb Exp Pharmacol; 2009; (191):71-92. PubMed ID: 19089326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis.
    Kyoi T; Oka M; Noda K; Ukai Y
    Life Sci; 2004 Aug; 75(15):1833-42. PubMed ID: 15302227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular genetics of the phosphodiesterases (PDEs).
    Azevedo MF; Faucz FR; Bimpaki E; Horvath A; Levy I; de Alexandre RB; Ahmad F; Manganiello V; Stratakis CA
    Endocr Rev; 2014 Apr; 35(2):195-233. PubMed ID: 24311737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
    Castro A; Jerez MJ; Gil C; Martinez A
    Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
    Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
    Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic nucleotide phosphodiesterases.
    Essayan DM
    J Allergy Clin Immunol; 2001 Nov; 108(5):671-80. PubMed ID: 11692087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-time monitoring of phosphodiesterase inhibition in intact cells.
    Herget S; Lohse MJ; Nikolaev VO
    Cell Signal; 2008 Aug; 20(8):1423-31. PubMed ID: 18467075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic nucleotide-dependent phosphodiesterases (PDEI) inhibition by muscarinic antagonists in bovine tracheal smooth muscle.
    Guerra de González L; González de Alfonzo R; Lippo de Bécemberg I; Alfonzo MJ
    Biochem Pharmacol; 2004 Aug; 68(4):651-8. PubMed ID: 15276072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential activation and inhibition of the multiple forms of cyclic nucleotide phosphodiesterase.
    Weiss B
    Adv Cyclic Nucleotide Res; 1975; 5():195-211. PubMed ID: 165666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.
    Andersson KE; Uckert S; Stief C; Hedlund P
    Neurourol Urodyn; 2007 Oct; 26(6 Suppl):928-33. PubMed ID: 17806124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
    Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
    Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense inhibition of phosphodiesterase expression.
    Epstein PM
    Methods; 1998 Jan; 14(1):21-33. PubMed ID: 9500855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cyclic nucleotides phosphodiesterases inhibitors].
    Hagiwara M; Hidaka H
    Nihon Rinsho; 1991 Sep; 49(9):1993-8. PubMed ID: 1660084
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.